Results 181 to 190 of about 301,296 (304)

Incidence and Predictors of Anticoagulant-Associated Bleeding in Patients With Venous Thromboembolism. [PDF]

open access: yesJ Clin Med Res
Thamgrang T   +6 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh   +4 more
wiley   +1 more source

Investigating risk factors and developing a predictive model for venous thromboembolism in patients with sepsis. [PDF]

open access: yesFront Med (Lausanne)
Han Y   +10 more
europepmc   +1 more source

Cardiometabolic Protein Profile Changes During Gender‐Affirming Hormone Therapy: A Prospective Clinical Study

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Cardiovascular disease (CVD) risk is elevated in transgender individuals during gender‐affirming hormone therapy (GAHT) with expected different mechanisms between T‐ and E2‐based GAHT. We investigated prospective changes in cardiometabolic proteins relating to complement, inflammation, and transport during GAHT.
Emilie Bukh Madsen   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy